OncNGS
  • Home
  • Call for tenders (closed)
  • About OncNGS
  • Phases
    • Pre-commercial Procedure
    • Phase 0 : Curiosity Driven Research
    • Open Market Consultation
    • Phase I : Solution design
    • Phase II: Prototype development
    • Phase III : Clinical validation of a limited set of pre-commercial devices
  • FAQ
  • News
  • Contact
  • Workspace
  • Home
  • Call for tenders (closed)
  • About OncNGS
  • Phases
    • Pre-commercial Procedure
    • Phase 0 : Curiosity Driven Research
    • Open Market Consultation
    • Phase I : Solution design
    • Phase II: Prototype development
    • Phase III : Clinical validation of a limited set of pre-commercial devices
  • FAQ
  • News
  • Contact
  • Workspace

oncNGS consortium conducted site visits to phase 2 contractors

oncNGS consortium conducted site visits to phase 2 contractors
2024-05-02
by Editorial team

On the 14, 20 and 26 March 2024, the monitoring team of the oncNGS consortium conducted three site visits on the premises (laboratory) of the oncNGS phase 2 contractors. The three site visits took place in Waldbronn, Germany for Agilent Technologies Belgium; in Leuven, Belgium for  KU Leuven; and in Vienna, Austria for ViennaLab Diagnostics, as part of the Hufiat Cancer Liquidation consortium formed by Euformatics Oy (lead tenderer), Oncompas Medicine, and ViennaLab Diagnostics. We were especially glad and interested by the exchanges we had with them about the work they are performing. The members of the oncNGS monitoring team who performed the site visits were: Gordana Raicevic, Aline Hebrant, Hélène Antoine-Poirel (SCIENSANO); Luca Mazzarella, Gianmaria Frigè, Patrizio Giacomini (ALLEANZA CONTRO IL CANCRO); Maud Kamal, Nicolas Servant (INSTITUT CURIE); Olga Blau (CHARITE – UNIVERSITAETSMEDIZIN BERLIN); and Claude Van Campenhout (INSTITUT JULES BORDET).

Share us on:
  • Home
  • About
  • Phases
  • Open Market Consultation
  • News
  • Contact
  • Login
  • FAQ

Articles récents

  • OncNGS enters Phase 3 of the PCP with two innovative solutions for cancer NGS testing
  • oncNGS consortium conducted site visits to phase 2 contractors
  • OncNGS has entered in prototyping phase (Phase 2) with the selection of three innovative approaches for future Next-Generation Sequencing (NGS) tests for cancer
  • Update on the current stage of the oncNGS Pre-Commercial Procurement procedure
  • The oncNGS consortium selects 4 innovative ideas for the research and development of Next Generation Sequencing solutions for cancer tests

Archives

  • janvier 2025
  • mai 2024
  • septembre 2023
  • février 2023
  • juillet 2022
  • juin 2022
  • mars 2022
  • janvier 2022
  • décembre 2021
  • novembre 2021
  • septembre 2021
  • août 2021
  • juin 2021
  • mai 2021
  • avril 2021
  • mars 2021

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 874467

Follow us:

© OncNGS

  • Privacy policy
  • Disclaimer